| Q53091777 | A case of CD138-/CD19+/CD4+ IgD plasma cell leukemia. |
| Q33495055 | Aggressive course of primary plasma cell leukemia with unusual morphological and cytogenetic features |
| Q36331788 | Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents |
| Q36173728 | Clinico-pathological spectrum of primary plasma cell leukemia diagnosed at a tertiary care centre in South India over 5 year period |
| Q41142668 | Complications and supportive therapy of multiple myeloma |
| Q58010291 | Cytogenetic and Fluorescence In Situ Hybridization Studies in Four Cases of Plasma Cell Leukemia |
| Q41342046 | DNA cell content studies in multiple myeloma |
| Q49641900 | Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry |
| Q60204034 | Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization |
| Q80238489 | Efficacy and safety of bortezomib in patients with plasma cell leukemia |
| Q44024556 | Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma |
| Q36393997 | Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance |
| Q47934970 | Frequent upregulation of MYC in plasma cell leukemia |
| Q44962191 | Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party |
| Q37486780 | Genetic aberrations and survival in plasma cell leukemia |
| Q37875193 | Guidelines for the diagnosis and management of multiple myeloma 2011. |
| Q35742685 | Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research |
| Q33402555 | How I treat plasma cell leukemia |
| Q38326852 | IgA plasma cell leukemia |
| Q41142643 | Immunophenotype and DNA cell content in multiple myeloma |
| Q36381306 | Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. |
| Q40996480 | Localized Relapse of Primary Plasma Cell Leukaemia in the Central Nervous System |
| Q46364364 | Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization |
| Q34677783 | Newly diagnosed multiple myeloma |
| Q33331137 | Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia |
| Q64228965 | Plasma Cell Leukemia: Definition, Presentation, and Treatment |
| Q33708734 | Plasma cell leukaemia and other aggressive plasma cell malignancies |
| Q74267084 | Plasma cell leukemia |
| Q33393995 | Plasma cell leukemia |
| Q73585716 | Plasma cell leukemia evolving into aggressive extramedullary plasmacytoma by clonal selection |
| Q34523175 | Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature |
| Q37424886 | Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis |
| Q35851641 | Plasma cell leukemia: case series from a tertiary center with review of literature |
| Q37810276 | Plasma cell leukemia: concepts and management |
| Q33956990 | Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group |
| Q38380625 | Plasma cell leukemia: from biology to treatment |
| Q52838137 | Plasma cell leukemia: update on biology and therapy. |
| Q37901231 | Plasma cell myeloma and related neoplasms |
| Q38781794 | Primary Plasma Cell Leukemia: Identity Card 2016. |
| Q34134838 | Primary plasma cell leukaemia: a report of 18 cases |
| Q33829100 | Primary plasma cell leukemia and autologous stem cell transplantation |
| Q34436631 | Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature |
| Q90170803 | Primary plasma cell leukemia: A case report and review of the literature |
| Q84820019 | Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004 |
| Q36185955 | Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols |
| Q34552588 | Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. |
| Q37746021 | Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia |
| Q34173892 | Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. |
| Q52663601 | Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. |
| Q42223210 | Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient |
| Q57452857 | Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents |
| Q47140962 | The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). |
| Q40836024 | Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation |
| Q33379649 | Thirty patients with primary plasma cell leukemia: a single center experience |
| Q43734900 | Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone |
| Q34019590 | Trends in survival of patients with primary plasma cell leukemia: a population-based analysis |
| Q46817722 | Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia |
| Q47783265 | cCD79a expression in a case of plasma cell leukemia |